Navigation Links
Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Date:6/19/2012

CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies.

The Phase 1 clinical trial of AZD2820 was halted by the Safety Review Committee established by AstraZeneca after meeting a predefined stopping criterion. The stopping criterion was a serious adverse event. It is suspected that the subject may have had an allergic reaction following his first dose. The subject was treated at the clinical site and has fully recovered. A review and investigation of the incident has commenced.

"We are pleased that the subject has fully recovered from this unfortunate adverse event and we will work closely with our partner AstraZeneca to investigate the cause of this incident and the overall plans for the AZD2820 program," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "AstraZeneca has confirmed their remaining commitment to the continued advancement of melanocortin agonists for treatment of obesity, including a number of collaboration compounds in various stages of preclinical testing."

The phase I single center study, conducted by AstraZeneca, targeted enrolling 72 obese but otherwise healthy male subjects, with a body mass index between 30 and 35 kg/m2, in a randomized, single-blind, placebo-controlled, trial. Eleven subjects had completed their dosing regimen prior to the halting of the trial. The primary outcome of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820 after administration of multiple ascending doses. Another Phase 1 single ascending dose study of AZD2820 was finalize
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
2. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
8. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
9. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
10. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
11. Metamaterials, quantum dots show promise for new technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... July 24, 2014 Your cell ... in modeling lithium-ion battery storage capacity. , New ... a theoretical model created at Lawrence Livermore ... that predicts how carbon components will perform as ... emphasizes the urgent need for higher-performance batteries. Several ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... N.J. , July 24, 2014 ... provider of regulatory and ethical review services for ... Alliance Biosciences. Formerly a division of ... was the leading biosafety and biosecurity consulting firm ... With this addition, WCG,s biosafety division – WCG ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
... , , DUBLIN, Ohio, ... to acquire the assets of privately held Biotech, an operator ... the Southwestern United States. , , Cardinal ... pharmacies and operates 26 cyclotron-based PET radiopharmaceutical manufacturing facilities. These ...
... ... for Jatropha Promotion & Biodiesel (CJP) a big breakthrough in the search for a viable ... of successful field trials, CJP is now happy to announce the much awaited commercial release ... ...
... ... Terrosa Technologies, a provider of Cloud and SaaS migration services ... sales, marketing and distribution responsibilities with Integrated Clinical Solutions for ... Trial Management System (CTMS) tool for the pharmaceutical clinical research ...
Cached Biology Technology:Cardinal Health Completes Biotech Acquisition 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 2Jatropha Couple Oil Crop Cultivation Technology Commercially Released 3Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 2Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software 3
(Date:7/24/2014)... arose have been maintained in our cells today according to ... today in the Journal of Biological Chemistry reveals ... animals still perform ancient reactions thought to have been responsible ... ago. , The primordial soup theory suggests that life began ... combination of metals, gases from the atmosphere and some form ...
(Date:7/24/2014)... work with a new drug that successfully treated lupus in ... received a $250,000 grant to expand his research to a ... a wider range of autoimmune diseases., Chandra Mohan, Hugh Roy ... UH, previously published a study in Arthritis Research & Therapy ... lupus in mice and reduced the number of cases of ...
(Date:7/24/2014)... July 24, 2014 NXT-ID, Inc., (NXTD: OTCQB) a biometric ... its next generation smart wallet, Wocket™, was recently the topic of  ... interviewed Gino Pereira , CEO of NXT-ID, ... Mr. Gino Pereira explains ... of credit cards and walks host Anita Finley ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... turtles have been slow to give up the secrets ... For decades, paleontologists who study fossils and molecular biologists ... more closely related to birds and crocodiles or to ... Biological Laboratory in Bar Harbor, Maine, and their colleagues ...
... Bethesda, Md. (July 25, 2011)It,s no secret that ... a bevy of recent research suggests that these positive ... a new review article highlighting the results of more ... this topic, Michelle W. Voss, of the University of ...
... One of the latest attempts to boost the ... in which patients receive a therapeutic injection of their ... clinical trials for melanoma and neuroblastoma, has its limitations: ... outside the body for future re-injection is extremely expensive ...
Cached Biology News:Discovery places turtles next to lizards on family tree 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 2Exercise has numerous beneficial effects on brain health and cognition, review suggests 3Universal donor immune cells 2
This Dedicated 18" X 18" (45.7 X 45.7 cm.) shaker platforms are optimized for a particular flask clip size. Dedicated platforms come fully loaded with flask clips....
... VARIOKLAV 75 S and 135 S steam sterilizers ... bottoms combine the advantages of a double-walled device ... effective deaeration and drying by built-in jacket heater ... fast cooling. The chamber is free of furnishings ...
... Shakers combine high durability and performance ... The patented triple-counterbalanced heavy-duty mechanism ... run with heavy out-of-balance loads. ... contamination. The heavy stainless steel ...
... 4300 System features Saga GT , is ... automates electrophoresis, lane finding, location of standards, ... ,Saga GT is second generation software ... initially developed at the University of Washington ...
Biology Products: